Concepts (270)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 32 | 2023 | 299 | 5.460 |
Why?
|
| Cognition Disorders | 16 | 2020 | 396 | 3.870 |
Why?
|
| Dementia | 20 | 2023 | 230 | 3.590 |
Why?
|
| Cognition | 23 | 2022 | 528 | 2.160 |
Why?
|
| Neuropsychological Tests | 19 | 2019 | 383 | 1.810 |
Why?
|
| Aged | 66 | 2023 | 9658 | 1.580 |
Why?
|
| Apolipoprotein E4 | 7 | 2020 | 58 | 1.540 |
Why?
|
| Apolipoproteins E | 7 | 2019 | 101 | 1.340 |
Why?
|
| Aging | 8 | 2022 | 876 | 1.310 |
Why?
|
| Residence Characteristics | 6 | 2022 | 166 | 1.240 |
Why?
|
| Humans | 87 | 2023 | 29541 | 1.210 |
Why?
|
| Female | 69 | 2023 | 18476 | 1.190 |
Why?
|
| Aged, 80 and over | 35 | 2023 | 3750 | 1.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 11 | 2022 | 1555 | 1.090 |
Why?
|
| Male | 53 | 2022 | 18199 | 0.940 |
Why?
|
| Cholesterol | 3 | 2019 | 232 | 0.940 |
Why?
|
| Diet | 5 | 2023 | 350 | 0.930 |
Why?
|
| Women's Health | 8 | 2023 | 224 | 0.880 |
Why?
|
| Risk Factors | 24 | 2023 | 3572 | 0.880 |
Why?
|
| Cardiovascular Diseases | 8 | 2022 | 1050 | 0.870 |
Why?
|
| Atherosclerosis | 3 | 2022 | 724 | 0.840 |
Why?
|
| Sleep | 2 | 2018 | 85 | 0.790 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2022 | 950 | 0.760 |
Why?
|
| Inflammation | 3 | 2019 | 510 | 0.740 |
Why?
|
| Brain | 8 | 2021 | 949 | 0.740 |
Why?
|
| Resilience, Psychological | 1 | 2019 | 15 | 0.720 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2020 | 46 | 0.720 |
Why?
|
| Lipoproteins, LDL | 1 | 2019 | 77 | 0.690 |
Why?
|
| Delirium | 1 | 2018 | 13 | 0.670 |
Why?
|
| Environment | 1 | 2018 | 50 | 0.670 |
Why?
|
| Social Environment | 1 | 2018 | 73 | 0.660 |
Why?
|
| Lipids | 1 | 2019 | 215 | 0.630 |
Why?
|
| Membrane Transport Proteins | 2 | 2019 | 37 | 0.620 |
Why?
|
| Longevity | 3 | 2014 | 22 | 0.580 |
Why?
|
| Utah | 11 | 2012 | 15 | 0.540 |
Why?
|
| Middle Aged | 24 | 2022 | 11220 | 0.530 |
Why?
|
| Cross-Cultural Comparison | 1 | 2014 | 25 | 0.510 |
Why?
|
| Incidence | 11 | 2022 | 1103 | 0.510 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 37 | 0.490 |
Why?
|
| Dementia, Vascular | 5 | 2020 | 13 | 0.480 |
Why?
|
| Proportional Hazards Models | 9 | 2018 | 727 | 0.470 |
Why?
|
| Vitamin E | 3 | 2008 | 21 | 0.470 |
Why?
|
| Longitudinal Studies | 11 | 2018 | 709 | 0.460 |
Why?
|
| Postmenopause | 4 | 2019 | 398 | 0.460 |
Why?
|
| Cohort Studies | 10 | 2022 | 1724 | 0.440 |
Why?
|
| Overweight | 5 | 2022 | 256 | 0.440 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2008 | 70 | 0.440 |
Why?
|
| Prevalence | 8 | 2022 | 897 | 0.410 |
Why?
|
| Memory Disorders | 1 | 2012 | 61 | 0.410 |
Why?
|
| Weight Loss | 6 | 2022 | 413 | 0.410 |
Why?
|
| Polymorphism, Genetic | 1 | 2012 | 214 | 0.410 |
Why?
|
| Life Style | 6 | 2022 | 372 | 0.390 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2022 | 49 | 0.370 |
Why?
|
| Obesity | 7 | 2022 | 1084 | 0.360 |
Why?
|
| Agricultural Workers' Diseases | 1 | 2010 | 86 | 0.360 |
Why?
|
| Sex Characteristics | 3 | 2020 | 175 | 0.360 |
Why?
|
| Genotype | 5 | 2012 | 826 | 0.340 |
Why?
|
| Follow-Up Studies | 11 | 2020 | 2133 | 0.330 |
Why?
|
| Risk | 5 | 2021 | 295 | 0.330 |
Why?
|
| Pesticides | 1 | 2010 | 190 | 0.320 |
Why?
|
| Occupational Exposure | 1 | 2010 | 225 | 0.310 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2021 | 1234 | 0.310 |
Why?
|
| Cerebrovascular Disorders | 2 | 2011 | 50 | 0.300 |
Why?
|
| Particulate Matter | 3 | 2022 | 28 | 0.300 |
Why?
|
| Dietary Supplements | 2 | 2008 | 171 | 0.290 |
Why?
|
| Odds Ratio | 3 | 2019 | 460 | 0.290 |
Why?
|
| Mortality | 1 | 2007 | 109 | 0.280 |
Why?
|
| Gene Frequency | 2 | 2010 | 274 | 0.280 |
Why?
|
| United States | 8 | 2022 | 3675 | 0.280 |
Why?
|
| Stroke | 2 | 2015 | 507 | 0.270 |
Why?
|
| Genome-Wide Association Study | 3 | 2022 | 615 | 0.270 |
Why?
|
| Memory | 2 | 2018 | 187 | 0.260 |
Why?
|
| Proxy | 1 | 2004 | 9 | 0.260 |
Why?
|
| Hormone Replacement Therapy | 3 | 2022 | 88 | 0.250 |
Why?
|
| Antihypertensive Agents | 5 | 2022 | 378 | 0.250 |
Why?
|
| Time Factors | 4 | 2020 | 2016 | 0.240 |
Why?
|
| Hypertension | 3 | 2022 | 980 | 0.230 |
Why?
|
| Factor Analysis, Statistical | 2 | 2013 | 70 | 0.220 |
Why?
|
| Diet, Mediterranean | 1 | 2022 | 23 | 0.220 |
Why?
|
| Vitamin B Complex | 1 | 2022 | 2 | 0.220 |
Why?
|
| Testosterone | 1 | 2022 | 47 | 0.220 |
Why?
|
| Gait | 1 | 2022 | 87 | 0.220 |
Why?
|
| Air Pollution | 1 | 2021 | 15 | 0.220 |
Why?
|
| Air Pollutants | 1 | 2021 | 18 | 0.220 |
Why?
|
| Risk Assessment | 4 | 2018 | 1317 | 0.220 |
Why?
|
| Health Status | 2 | 2019 | 362 | 0.210 |
Why?
|
| Mental Disorders | 2 | 2013 | 97 | 0.210 |
Why?
|
| Mass Screening | 1 | 2003 | 215 | 0.210 |
Why?
|
| Prospective Studies | 8 | 2022 | 2000 | 0.210 |
Why?
|
| Body Weight | 2 | 2020 | 297 | 0.210 |
Why?
|
| Disease Progression | 3 | 2013 | 595 | 0.200 |
Why?
|
| Age of Onset | 2 | 2018 | 100 | 0.200 |
Why?
|
| C-Reactive Protein | 2 | 2019 | 238 | 0.200 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 361 | 0.190 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2020 | 52 | 0.190 |
Why?
|
| Body Size | 1 | 2020 | 31 | 0.190 |
Why?
|
| Anthropometry | 1 | 2020 | 83 | 0.180 |
Why?
|
| Apolipoprotein C-I | 1 | 2019 | 4 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2019 | 15 | 0.180 |
Why?
|
| Problem Solving | 1 | 2018 | 27 | 0.170 |
Why?
|
| Gender Identity | 1 | 2018 | 18 | 0.170 |
Why?
|
| Forecasting | 1 | 2019 | 131 | 0.170 |
Why?
|
| Editorial Policies | 1 | 2018 | 13 | 0.170 |
Why?
|
| Cost of Illness | 1 | 2018 | 59 | 0.170 |
Why?
|
| Blood Pressure | 2 | 2022 | 874 | 0.160 |
Why?
|
| Geriatric Assessment | 2 | 2018 | 328 | 0.160 |
Why?
|
| Ascorbic Acid | 2 | 2008 | 20 | 0.160 |
Why?
|
| Sex Distribution | 2 | 2010 | 189 | 0.160 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 103 | 0.160 |
Why?
|
| Diet Surveys | 1 | 2017 | 56 | 0.160 |
Why?
|
| Logistic Models | 1 | 2019 | 734 | 0.160 |
Why?
|
| Databases, Factual | 1 | 2018 | 330 | 0.150 |
Why?
|
| Antioxidants | 2 | 2008 | 115 | 0.150 |
Why?
|
| Anorexia | 1 | 2016 | 4 | 0.150 |
Why?
|
| Decision Making | 1 | 2018 | 189 | 0.150 |
Why?
|
| Continental Population Groups | 1 | 2018 | 231 | 0.150 |
Why?
|
| Age Factors | 4 | 2015 | 1111 | 0.140 |
Why?
|
| Trace Elements | 1 | 2015 | 7 | 0.140 |
Why?
|
| Metals, Heavy | 1 | 2015 | 7 | 0.140 |
Why?
|
| Depressive Disorder, Major | 1 | 2016 | 35 | 0.140 |
Why?
|
| Ethnic Groups | 1 | 2018 | 453 | 0.140 |
Why?
|
| Translations | 1 | 2014 | 1 | 0.130 |
Why?
|
| Russia | 1 | 2014 | 2 | 0.130 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2014 | 10 | 0.130 |
Why?
|
| Phenotype | 2 | 2013 | 676 | 0.130 |
Why?
|
| Anticoagulants | 1 | 2015 | 121 | 0.130 |
Why?
|
| Language | 1 | 2013 | 43 | 0.120 |
Why?
|
| Executive Function | 1 | 2013 | 54 | 0.120 |
Why?
|
| Atrial Fibrillation | 2 | 2015 | 313 | 0.120 |
Why?
|
| Questionnaires | 2 | 2010 | 3 | 0.120 |
Why?
|
| Attention | 1 | 2013 | 82 | 0.120 |
Why?
|
| Registries | 1 | 2014 | 282 | 0.110 |
Why?
|
| Patient Selection | 1 | 2014 | 260 | 0.110 |
Why?
|
| Depression | 3 | 2022 | 363 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2015 | 1241 | 0.110 |
Why?
|
| Models, Statistical | 1 | 2013 | 161 | 0.110 |
Why?
|
| Menopause | 1 | 2012 | 86 | 0.110 |
Why?
|
| Exercise | 3 | 2023 | 567 | 0.110 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 716 | 0.110 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2012 | 183 | 0.100 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 1347 | 0.100 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2011 | 7 | 0.100 |
Why?
|
| Time | 1 | 2010 | 22 | 0.100 |
Why?
|
| Environmental Exposure | 2 | 2021 | 85 | 0.100 |
Why?
|
| Survival Analysis | 3 | 2010 | 465 | 0.100 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 80 | 0.100 |
Why?
|
| DNA Copy Number Variations | 1 | 2010 | 15 | 0.090 |
Why?
|
| Adult | 5 | 2023 | 8698 | 0.090 |
Why?
|
| Genetics | 1 | 2009 | 4 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2010 | 96 | 0.090 |
Why?
|
| Toxicology | 1 | 2009 | 6 | 0.090 |
Why?
|
| Sex Factors | 2 | 2015 | 637 | 0.090 |
Why?
|
| Neurotoxins | 1 | 2009 | 16 | 0.090 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2009 | 17 | 0.090 |
Why?
|
| Behavior | 1 | 2009 | 30 | 0.090 |
Why?
|
| Actins | 1 | 2009 | 54 | 0.090 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2009 | 76 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2008 | 63 | 0.090 |
Why?
|
| Age Distribution | 2 | 2007 | 201 | 0.080 |
Why?
|
| Mental Processes | 1 | 2008 | 17 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2016 | 914 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2010 | 283 | 0.080 |
Why?
|
| Confidence Intervals | 2 | 2005 | 139 | 0.080 |
Why?
|
| Neuroprotective Agents | 1 | 2007 | 20 | 0.080 |
Why?
|
| Carotenoids | 1 | 2007 | 9 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 134 | 0.080 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2013 | 90 | 0.070 |
Why?
|
| Causality | 1 | 2006 | 36 | 0.070 |
Why?
|
| Religion | 1 | 2006 | 28 | 0.070 |
Why?
|
| Statistics as Topic | 1 | 2006 | 106 | 0.070 |
Why?
|
| Genetics, Population | 1 | 2005 | 30 | 0.070 |
Why?
|
| Activities of Daily Living | 1 | 2006 | 214 | 0.070 |
Why?
|
| ROC Curve | 1 | 2003 | 149 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 868 | 0.060 |
Why?
|
| Anxiety | 2 | 2016 | 150 | 0.060 |
Why?
|
| Blood Proteins | 1 | 2023 | 21 | 0.060 |
Why?
|
| Autopsy | 2 | 2015 | 38 | 0.060 |
Why?
|
| Histamine H2 Antagonists | 1 | 2002 | 2 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 1 | 2023 | 47 | 0.060 |
Why?
|
| tau Proteins | 1 | 2023 | 38 | 0.060 |
Why?
|
| Antigens, Neoplasm | 1 | 2023 | 49 | 0.060 |
Why?
|
| Life Change Events | 1 | 2022 | 21 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 649 | 0.060 |
Why?
|
| Acceleration | 1 | 2022 | 57 | 0.060 |
Why?
|
| Vitamin B 12 | 1 | 2022 | 8 | 0.050 |
Why?
|
| Proteomics | 1 | 2023 | 91 | 0.050 |
Why?
|
| Rest | 1 | 2022 | 49 | 0.050 |
Why?
|
| Folic Acid | 1 | 2022 | 13 | 0.050 |
Why?
|
| Frail Elderly | 1 | 2022 | 59 | 0.050 |
Why?
|
| Loneliness | 1 | 2022 | 6 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 545 | 0.050 |
Why?
|
| Dioxygenases | 1 | 2021 | 2 | 0.050 |
Why?
|
| Public Health | 1 | 2022 | 70 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2022 | 104 | 0.050 |
Why?
|
| Cause of Death | 2 | 2018 | 223 | 0.050 |
Why?
|
| Estradiol | 1 | 2022 | 123 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2021 | 59 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 795 | 0.050 |
Why?
|
| Cytokines | 1 | 2022 | 244 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2021 | 161 | 0.050 |
Why?
|
| Vitamin D | 1 | 2022 | 173 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2022 | 210 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2020 | 3135 | 0.050 |
Why?
|
| Calcium | 1 | 2022 | 305 | 0.050 |
Why?
|
| Algorithms | 1 | 2003 | 469 | 0.050 |
Why?
|
| Quality of Life | 1 | 2006 | 799 | 0.050 |
Why?
|
| Erythrocytes | 1 | 2020 | 47 | 0.050 |
Why?
|
| Renin-Angiotensin System | 1 | 2022 | 247 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 114 | 0.050 |
Why?
|
| Thinness | 1 | 2020 | 30 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2020 | 156 | 0.050 |
Why?
|
| Waist Circumference | 1 | 2020 | 90 | 0.050 |
Why?
|
| Cerebrovascular Circulation | 1 | 2020 | 96 | 0.050 |
Why?
|
| Adiposity | 1 | 2020 | 209 | 0.040 |
Why?
|
| Weight Gain | 1 | 2020 | 106 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2018 | 7 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2018 | 14 | 0.040 |
Why?
|
| Organ Size | 1 | 2019 | 208 | 0.040 |
Why?
|
| Voluntary Health Agencies | 1 | 2018 | 1 | 0.040 |
Why?
|
| National Institute on Aging (U.S.) | 1 | 2018 | 7 | 0.040 |
Why?
|
| China | 1 | 2018 | 43 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2018 | 89 | 0.040 |
Why?
|
| Asian Americans | 1 | 2018 | 99 | 0.040 |
Why?
|
| Caloric Restriction | 1 | 2018 | 92 | 0.040 |
Why?
|
| Cholesterol, HDL | 1 | 2018 | 171 | 0.040 |
Why?
|
| Contraceptive Agents, Female | 1 | 2017 | 15 | 0.040 |
Why?
|
| Adiponectin | 1 | 2018 | 117 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2018 | 165 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2018 | 228 | 0.040 |
Why?
|
| Triglycerides | 1 | 2018 | 220 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 204 | 0.040 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2017 | 89 | 0.040 |
Why?
|
| Periodicals as Topic | 1 | 2018 | 96 | 0.040 |
Why?
|
| Guilt | 1 | 2016 | 1 | 0.040 |
Why?
|
| Research Design | 1 | 2018 | 276 | 0.040 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2017 | 125 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2018 | 154 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2020 | 889 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2015 | 172 | 0.030 |
Why?
|
| Survival Rate | 2 | 2007 | 821 | 0.030 |
Why?
|
| Comorbidity | 2 | 2007 | 547 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 1451 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2018 | 1209 | 0.030 |
Why?
|
| Irritable Mood | 1 | 2012 | 3 | 0.030 |
Why?
|
| Animals | 2 | 2018 | 7480 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2012 | 181 | 0.030 |
Why?
|
| Hispanic Americans | 1 | 2018 | 948 | 0.030 |
Why?
|
| Community Health Planning | 1 | 2011 | 9 | 0.030 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2011 | 27 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2010 | 34 | 0.020 |
Why?
|
| African Americans | 1 | 2018 | 1523 | 0.020 |
Why?
|
| Vascular Diseases | 1 | 2010 | 63 | 0.020 |
Why?
|
| Phylogeny | 1 | 2009 | 58 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2006 | 3156 | 0.020 |
Why?
|
| Angina Pectoris | 1 | 2007 | 19 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 275 | 0.020 |
Why?
|
| Food Habits | 1 | 2007 | 1 | 0.020 |
Why?
|
| Linear Models | 1 | 2008 | 430 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2007 | 30 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 285 | 0.020 |
Why?
|
| Coronary Artery Bypass | 1 | 2007 | 101 | 0.020 |
Why?
|
| Educational Status | 1 | 2007 | 162 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2007 | 204 | 0.020 |
Why?
|
| Hearing | 1 | 2006 | 11 | 0.020 |
Why?
|
| Vision, Ocular | 1 | 2006 | 30 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 1021 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2007 | 414 | 0.020 |
Why?
|
| Young Adult | 1 | 2010 | 2456 | 0.010 |
Why?
|
| Aspirin | 1 | 2002 | 60 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 302 | 0.010 |
Why?
|